Global Tumor Infiltrating Lymphocytes Market
Tumor Infiltrating Lymphocytes Global Market Report 2023: Sector to Reach $15.56 Billion by 2027 at a 13.7% CAGR
May 23, 2023 04:53 ET | Research and Markets
Dublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Tumor Infiltrating Lymphocytes Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global tumor infiltrating...
tiziana-logo.png
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
April 18, 2023 07:00 ET | Tiziana Life Sciences Ltd.
CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only...
logo.jpg
CD3 Antibodies Clinical Trials Market Size Companies Insight
March 21, 2023 04:27 ET | KuicK Research
Delhi, March 21, 2023 (GLOBE NEWSWIRE) -- Antibodies have transformed cancer treatment because of their flexible properties that allow them to be used as both antagonists and agonists. With the...
MacroGenics-Logo-(transparent-background).png
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
June 16, 2021 07:30 ET | MacroGenics, Inc.
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific moleculesMacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies
October 01, 2020 08:00 ET | TeneoBio, Inc
NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced today that their investigational new drug application (IND) for TNB-486, a bispecific...